Skip to Main Content
Peter Sguigna, M.D.

Peter Sguigna, M.D.

Assistant Professor

School
Medical School
Department
Neurology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Joined UT Southwestern: 2020

    Clinical Interests: Dr. Sguigna specializes in multiple sclerosis and related disorders. He sees patients with multiple sclerosis, optic neuritis, and other neuro-immunological disorders. He has clinical interest in those patients with neurological disease that have prominent visual symptoms or findings.

    Research: Dr. Sguigna's research interests and activities include advanced diagnostic imaging of neuro-ophthalmological disorders, as well as unraveling the neuro-retinal circuitry in neuroimmunological diseases. He actively works on better ways to distinguish these disorders using non-invasive technology. He uses specialized testing to gain insight into some of the most disabling symptoms for patients with multiple sclerosis. He leads multiple clinical trials for patients with multiple sclerosis to reduce disability, as well as symptoms such as fatigue and word finding difficulty.

    Trainee Education: Dr. Sguigna provides education to medical students, residents, and fellows rotating through his clinic and research laboratory. Occasionally he will invite high school students and undergraduate students for rotations, as education is a prominent goal of the department.

  • Education
    Medical School
    UT Southwestern Medical School (2014)
    Residency
    UT Southwestern Medical Center (2018), Neurology
    Fellowship
    UT Southwestern Medical Center (2020), Multiple Sclerosis
  • Research Interest
    • Clinical Treatment Trials
    • Medical Devices
    • MOG Antibody Associated Disorders
    • Multiple Sclerosis
    • Neuro-Ophthalmology
    • Neuromyelitis Optica Spectrum Disorder
    • Optic Neuritis
    • Visual Dysfunction
  • Publications
    Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials (Journal of Nanobiotechnology, (2023), 21, 1, (478), 10.1186/s12951-023-02236-z)
    Ren J, Dewey RB, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB, Greenberg BM Journal of Nanobiotechnology 2024 Dec 22
    Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design
    Sguigna PV, Hussain RZ, Okai A, Blackburn KM, Tardo L, Madinawala M, Korich J, Lebson LA, Kaplan J, Salter A, Manouchehri N, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
    Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials
    Ren J, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB, Greenberg BM Journal of Nanobiotechnology 2023 Dec 21
    Subclinical optic neuritis in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease
    Nguyen L, Wang CX, Conger DL, Sguigna PV, Singh S, Greenberg BM Multiple Sclerosis and Related Disorders 2023 Aug 76
    A narrative review of neuro-ophthalmologic disease in African Americans and Hispanics with multiple sclerosis
    Tardo L, Salter A, Truong-Le M, Horton L, Blackburn KM, Sguigna PV Therapeutic Advances in Chronic Disease 2023 Jan 14
    Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study
    Sguigna PV, Toranian S, Tardo LM, Blackburn KM, Horton LA, Conger D, Meltzer E, Hogan RN, McCreary M, Zee PC, Takahashi JS, Greenberg BM Multiple Sclerosis Journal - Experimental, Translational and Clinical 2023 Jan 9
    A cross-sectional natural history study of aspartylglucosaminuria
    Goodspeed K, Horton DK, Lowden A, Sguigna PV, Booth T, Wang ZJ, Edgar VB JIMD Reports 2022 Sep 63 425-433
    The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
    Hussain RZ, Sguigna PV, Okai A, Wright C, Madinawala M, Bass AD, Cutter GR, Manouchehri N, Stuve O Journal of Central Nervous System Disease 2022 Aug 14
    Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience
    Sguigna PV, Tardo LM, Blackburn KM, Horton LA, Conger DL, Hogan RN, McCreary MC, Greenberg BM Neuro-Ophthalmology 2022 46 375-382
    Asymptomatic retinal vasculopathy in neuropsychiatric systemic lupus erythematosus
    Sguigna PV, Tardo L, Conger D, Hogan R, Greenberg BM Journal of the Neurological Sciences 2021 Nov 430